[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vertex Pharmaceuticals Incorporated\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":402},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,42,65,89,115,137,159,210,233,254,275,294,316,335,353,376],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100631516","phase-2-a-phase-2-study-to-evaluate-povetacicept-in-adults-with-generalized-myasthenia-gravis-100631516",false,"NCT07501702","A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis","ETNA","Key Inclusion Criteria:\n\n* Age 18-80 years\n* Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV\n* Additional inclusion criteria are defined in the protocol\n\nKey Exclusion Criteria:\n\n* History of thymic surgery within 6 months of screening\n* History of malignancy within the last 5 years\n* Additional exclusion criteria are defined in the protocol\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.","ALL","18 Years","80 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).",[28],"Myasthenia Gravis, Generalized","RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-29","ACTUAL",{"date":35,"type":33},"2026-05-13",{"date":37,"type":22},"2029-03-02",{"name":39,"class":40},"Vertex Pharmaceuticals Incorporated","INDUSTRY",17,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100608647","phase-2-evaluation-of-efficacy-safety-and-tolerability-of-povetacicept-in-participants-with-primary-membranous-nephropathy-pmn-100608647","NCT07204275","Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)","A Phase 2b\u002F3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy","OLYMPUS","Key Inclusion Criteria:\n\n• Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility\n\nKey Exclusion Criteria:\n\n• Hypersensitivity to investigational medicinal product or to any of its excipients\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply","75 Years",{"count":52,"type":22},176,[25,54],"PHASE3","The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).",[57],"Primary Membranous Nephropathy",{"date":32,"type":33},{"date":60,"type":33},"2025-09-30",{"date":62,"type":22},"2028-12-29",{"name":39,"class":40},102,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100422855","phase-3-a-safety-tolerability-and-efficacy-study-of-vx-880-in-participants-with-type-1-diabetes-100422855","NCT04786262","A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes","A Phase 1\u002F2\u002F3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia","Key Inclusion Criteria:\n\n* Clinical history of T1D with \\> 5 years of duration of insulin dependence\n* At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment\n* Stable diabetic treatment\n* Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study\n\nKey Exclusion Criteria:\n\n-Prior islet cell transplant, organ transplant, or cell therapy\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply","65 Years",{"count":74,"type":22},52,[54],"This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.",[78,79,80],"Diabetes Mellitus, Type 1","Impaired Hypoglycemic Awareness","Severe Hypoglycemia",{"date":82,"type":33},"2026-06-30",{"date":84,"type":33},"2021-03-29",{"date":86,"type":22},"2030-06-30",{"name":39,"class":40},29,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":72,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100463298","phase-2-phase-23-adaptive-study-of-vx-147-in-adult-and-pediatric-participants-with-apol1-mediated-proteinuric-kidney-disease-100463298","NCT05312879","Phase 2\u002F3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease","A Phase 2\u002F3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease","AMPLITUDE","Key Inclusion Criteria:\n\nPart A:\n\n* APOL1 genotype of G1\u002FG1, G2\u002FG2, or G1\u002FG2\n* Proteinuric kidney disease\n\nPart B:\n\n\\- Completion of Treatment Period in Part A and no permanent discontinuation of study drug.\n\nKey Exclusion Criteria:\n\nPart A:\n\n* Solid organ or bone marrow transplant\n* Uncontrolled hypertension\n* History of diabetes mellitus\n* Known underlying cause of kidney disease including but not limited to sickle cell disease\n\nPart B:\n\n* ESKD (End Stage Kidney Disease) as defined in the protocol.\n* Any lab abnormality that may pose a safety risk to the participant, as judged by the investigator.\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.","10 Years",{"count":99,"type":22},466,[25,54],"The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.",[103],"Proteinuric Kidney Disease",[105],"APOL1-mediated kidney disease (AMKD)","2026-06-24",{"date":108,"type":33},"2026-06-25",{"date":110,"type":33},"2022-03-30",{"date":112,"type":22},"2030-05-07",{"name":39,"class":40},318,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100564417","phase-3-evaluation-of-efficacy-and-safety-of-suzetrigine-for-pain-associated-with-diabetic-peripheral-neuropathy-100564417","NCT06628908","Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy","A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy","Key Inclusion Criteria:\n\n* Body weight greater than or equal to (≥) 45 kilogram (kg)\n* Body mass index (BMI) ≥18.0 to less than (\\\u003C) 40.0 kilogram per meter square (kg\u002Fm\\^2)\n* Diagnosis of diabetes mellitus type 1 or type 2 by glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN\n* Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period\n\nKey Exclusion Criteria:\n\n* More than 3 missing daily NPRS scores during the 7-day Baseline Period\n* Any sensory abnormality (excluding DPN) as pre-specified in the protocol\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":123,"type":22},1100,[54],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).",[127],"Diabetic Peripheral Neuropathic Pain","2026-06-12",{"date":130,"type":33},"2026-06-15",{"date":132,"type":33},"2024-10-01",{"date":134,"type":22},"2027-05-31",{"name":39,"class":40},76,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},"100605324","phase-2-phase-2a-study-of-vx-407-in-participants-with-adpkd-who-have-a-subset-of-pkd1-gene-variants-aglow-100605324","NCT07161037","Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)","A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants","AGLOW","Key Inclusion Criteria:\n\n* A pre-existing diagnosis of ADPKD as defined in the protocol\n* Willing and able to comply with scheduled visits and other study procedures\n* Participants with ADPKD with Mayo imaging classification (MIC) status of 1B (with htTKV ≥250 mL\u002Fm), 1C, 1D, or 1E confirmed by abdominal MRI obtained during screening\n* Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 25 milliliter per minute (mL\u002Fmin)\u002F1.73 square meter (m\\^2)\n\nKey Exclusion Criteria:\n\n* History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD\n* History of solid organ or bone marrow transplantation or nephrectomy\n* Ongoing renal replacement therapy or planning to start renal replacement therapy within 12 months of screening\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.",{"count":146,"type":22},24,[25],"The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.",[150],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","2026-06-11",{"date":130,"type":33},{"date":154,"type":33},"2025-11-19",{"date":156,"type":22},"2027-12-31",{"name":39,"class":40},43,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":209},"100530360","phase-1-a-phase-12-study-of-vx-670-in-adult-participants-with-myotonic-dystrophy-1-dm1-100530360","NCT06185764","A Phase 1\u002F2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)","A Phase 1\u002F2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1","Galileo","Key Inclusion Criteria:\n\n\\- Documented clinical diagnosis of DM1 with age of onset greater than (\\>) 1 year of age and documented positive genetic test for DM1 in the subject with cytosine thymine guanine (CTG) repeat of at least 100\n\nKey Exclusion Criteria:\n\n\\- History of any illness or any clinical condition as pre-specified in the protocol\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.","64 Years",{"count":74,"type":22},[170,25],"PHASE1","The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.",[173],"Myotonic Dystrophy Type 1 (DM1)",[175,176,177,178,173,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200],"DM1","DM2","Myotonic Dystrophy 1","Myotonic Dystrophy 2","Myotonic Dystrophy","DM","Myotonia","Dystrophy Myotonic","Myotonic Disorders","Steinert Disease","Vertex","Entrada","VX-670","VX670","PMO","ASO","Myotonic Muscular Dystrophy","Muscular Disorders, Atrophic","Muscular Diseases","Musculoskeletal Diseases","Neuromuscular Diseases","Nervous System Diseases","Genetic Diseases, Inborn","Heredodegenerative Disorders, Nervous System","Neurodegenerative Diseases","Muscular Dystrophies","2026-06-05",{"date":203,"type":33},"2026-06-08",{"date":205,"type":33},"2024-02-20",{"date":207,"type":22},"2027-02-02",{"name":39,"class":40},26,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":217,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},"100643784","phase-1-a-phase-1-first-in-human-study-of-vx-433-100643784","NCT07584434","A Phase 1, First-in-human Study of VX-433","A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion","Key Inclusion Criteria:\n\n* Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg\u002Fm2), inclusive\n* A total body weight of more than (\\>) 50 kg\n* Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening\n\nKey Exclusion Criteria:\n\n* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug\n* Any condition possibly affecting drug absorption\n* For female participants: of childbearing potential, pregnant, breastfeeding, or planning to become pregnant or donate ova during the study or within 90 days after last dose of study drug\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.",true,"55 Years",{"count":220,"type":22},118,[170],"The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.",[224],"Narcolepsy Type 1 (NT1)","2026-06-04",{"date":203,"type":33},{"date":228,"type":33},"2026-05-21",{"date":230,"type":22},"2027-03-05",{"name":39,"class":40},1,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":253},"100563722","phase-2-evaluation-of-efficacy-and-safety-of-vx-993-for-pain-associated-with-diabetic-peripheral-neuropathy-100563722","NCT06619860","Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy","A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy","Key Inclusion Criteria:\n\n* Diagnosis of diabetes mellitus type 1 or type 2 with\n\n  * Glycosylated hemoglobin A1c (HbA1c) less than or equal to (≤) 9% and\n  * Presence of bilateral pain in lower extremities due to DPN (defined as a symmetric, length-dependent sensory or sensorimotor polyneuropathy) for at least 1 year\n\nKey Exclusion Criteria:\n\n* Painful neuropathy other than DPN\n* History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)\n* History of a clinical atherosclerotic event, such as myocardial infarction or stroke, within the past 12 months\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":241,"type":22},300,[25],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)",[127],"2026-05-29",{"date":247,"type":33},"2026-06-01",{"date":249,"type":33},"2024-10-18",{"date":251,"type":22},"2027-04-22",{"name":39,"class":40},47,{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},"100610733","phase-3-evaluation-of-efficacy-and-safety-of-suzetrigine-suz-for-pain-associated-with-diabetic-peripheral-neuropathy-100610733","NCT07231419","Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy","A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy","Key Inclusion Criteria:\n\n* Body weight greater than or equal to (≥)45 kilogram (kg)\n* Body mass index (BMI) ≥18 to less than (\\\u003C) 40 kilogram per meter square (kg\u002Fm\\^2)\n* Diagnosis of diabetes mellitus type 1 or type 2 and with glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN for at least 1 year\n* Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period\n\nKey Exclusion Criteria:\n\n* More than 3 missing daily NPRS scores during the 7-day Baseline Period\n* Received Journavx within 30 days of study drug dosing\n* Any sensory abnormality (excluding DPN) as pre-specified in the protocol\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":262,"type":22},734,[54],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).",[127],"2026-05-18",{"date":268,"type":33},"2026-05-19",{"date":270,"type":33},"2025-11-21",{"date":272,"type":22},"2027-04-06",{"name":39,"class":40},75,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":217,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":232},"100614759","phase-1-dose-escalation-study-evaluating-the-safety-and-pharmacokinetics-of-vx-581-in-healthy-participants-100614759","NCT07283770","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants","A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects","Key Inclusion Criteria:\n\n* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg\u002Fm\\^2)\n* A total body weight of more than (\\>) 50 kg\n* Male and Female participants of non-childbearing potential\n\nKey Exclusion Criteria:\n\n* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug\n* Any condition possibly affecting drug absorption\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":283,"type":22},128,[170],"The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.",[287],"Cystic Fibrosis",{"date":266,"type":33},{"date":290,"type":33},"2025-12-09",{"date":292,"type":22},"2026-11-19",{"name":39,"class":40},{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},"100634352","phase-4-evaluation-of-pain-treatment-after-total-knee-arthroplasty-100634352","NCT07538570","Evaluation of Pain Treatment After Total Knee Arthroplasty","A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty","Key Inclusion Criteria:\n\n* Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg\u002Fm\\^2)\n* Scheduled to undergo an elective primary unilateral TKA surgery\n\nKey Exclusion Criteria:\n\n\\- History of previous TKA surgery on incident side\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.",{"count":302,"type":22},60,[304],"PHASE4","The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).",[307],"Pain","2026-05-08",{"date":35,"type":33},{"date":311,"type":33},"2026-04-24",{"date":313,"type":22},"2027-01-30",{"name":39,"class":40},2,{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":217,"sex":323,"minAge":18,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":232},"100622072","phase-1-evaluation-of-the-excretion-of-suzetrigine-into-breast-milk-in-healthy-lactating-female-participants-100622072","NCT07378865","Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants","A Phase 1, Open-label, Single-dose Study Evaluating the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Subjects","Key Inclusion Criteria:\n\n* Body mass index of greater than or equal to (≥) 18.0 to less than (\\\u003C) 40.0 kilogram per meter square (Kg\u002Fm\\^2) at the Screening Visit\n* Participants between 6 weeks and 12 months (inclusive) postpartum from a pregnancy of at least 37 weeks gestation, as of Day 1\n* Willing to perform regular pumping to maintain milk supply for the duration of the study\n* Participants with well-established lactation, defined as breastfeeding and\u002For pumping at least 3 times per day\n* Participant agrees to abstain from donating or feeding their infant any breast milk produced after receiving SUZ through the completion of the Safety Follow-up Visit (SFUV)\n\nKey Exclusion Criteria:\n\n* History of febrile illness or other acute illness that has not fully resolved within 14 days before study drug dosing\n* History of breast implants, breast augmentation, or breast reduction surgery that significantly impacts breastfeeding or collection of milk from one or both breasts\n* History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant\n* Pregnant or planning to become pregnant during the study or within 30 days after receiving study drug\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.","FEMALE",{"count":325,"type":22},12,[170],"The purpose of the study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ) and its active metabolite in breast milk of lactating female participants. In addition, the purpose is also to evaluate the relative infant dose (RID), safety and tolerability of SUZ and its active metabolite in lactating female participants.",[307],{"date":35,"type":33},{"date":331,"type":33},"2026-02-13",{"date":333,"type":22},"2027-02-26",{"name":39,"class":40},{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":217,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":232},"100626551","phase-1-dose-escalation-study-evaluating-the-safety-and-pharmacokinetics-of-vx-272-in-healthy-participants-100626551","NCT07437105","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants","A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects",{"count":283,"type":22},[170],"The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.",[287],"2026-03-25",{"date":347,"type":33},"2026-03-31",{"date":349,"type":33},"2026-02-25",{"date":351,"type":22},"2027-03-23",{"name":39,"class":40},{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":375},"100580062","phase-3-an-efficacy-safety-and-tolerability-study-of-vx-880-in-participants-with-type-1-diabetes-with-a-kidney-transplant-100580062","NCT06832410","An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant","A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant","Key Inclusion Criteria:\n\n* Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence\n* Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks\n* Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study\n\nKey Exclusion Criteria:\n\n* Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks\n* Participants had \\>1 kidney transplant procedure\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":361,"type":22},10,[54],"This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.",[365,366],"Type 1 Diabetes","Kidney Transplant","2026-03-18",{"date":369,"type":33},"2026-03-23",{"date":371,"type":33},"2025-03-31",{"date":373,"type":22},"2027-09-17",{"name":39,"class":40},7,{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":17,"minAge":383,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":401},"100475948","phase-3-evaluation-of-efficacy-and-safety-of-a-single-dose-of-ctx001-in-participants-with-transfusion-dependent--thalassemia-and-severe-sickle-cell-disease-100475948","NCT05477563","Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease","A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease","Key Inclusion Criteria:\n\n* Participants with TDT and SCD:\n* Eligible for autologous stem cell transplant as per investigator's judgment.\n* Participants with TDT:\n* Diagnosis of TDT as defined by:\n* Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia\u002Fhemoglobin E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning\n* History of at least 100 milliliter (mL)\u002Fkilograms (kg)\u002Fyear or 10 units\u002Fyear of packed red blood cells (RBC) transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening\n* Participants with SCD:\n* Diagnosis of severe SCD as defined by:\n* Documented SCD genotypes\n* History of at least two severe VOCs events per year for the previous two years prior to enrollment\n\nKey Exclusion Criteria:\n\n* Participants with TDT and SCD:\n* A willing and healthy 10\u002F10 human leukocyte antigen (HLA)-matched related donor is available per investigator's judgement\n* Prior hematopoietic stem cell transplant (HSCT)\n* Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator\n* Participants with TDT:\n* Participants with associated α-thalassemia and \\>1 alpha deletion, or alpha multiplications\n* Participants with sickle cell β-thalassemia variant\n* Participants with SCD:\n* History of untreated moyamoya syndrome or presence of moyamoya syndrome at screening\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.","12 Years","35 Years",{"count":209,"type":22},[54],"This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.",[389,390,391,197,392,393,394],"Beta-Thalassemia","Thalassemia","Hematologic Diseases","Hemoglobinopathies","Sickle Cell Disease","Sickle Cell Anemia",{"date":369,"type":33},{"date":397,"type":33},"2022-08-02",{"date":399,"type":22},"2027-06-09",{"name":39,"class":40},6,""]